KPV

Also known as: Î±-MSH(11-13), Alpha-MSH fragment

Evidence Tier Cmed-high riskintermediatenot approved

Anti-inflammatory Î±-MSH tripeptide fragment studied in cell and animal models for NF-ÎºB inhibition.

Not Approved

This substance is not approved by any major regulatory body for human therapeutic use. All information is derived from preclinical research, limited clinical studies, or off-label contexts.

Overview

KPV is a tripeptide fragment of Î±-MSH (residues 11-13) with reported anti-inflammatory effects. Studies show inhibition of NF-ÎºB signaling in cell models. Evidence is primarily in vitro and animal model; dosing varies widely. Limited direct human data. Used in dermatitis/inflammation and skin/gut inflammation research contexts.

Research Details

Mechanism of Action

Anti-inflammatory effects via inhibition of NF-ÎºB signaling (cell models).

Study Dose Range

In vitro and animal models; dosing varies widely.

Administration Routes

topical, subcutaneous

Onset / Timeline

Cell signaling endpoints are acute; clinical translation unknown.

Expected Effects

Preclinical anti-inflammatory effects; skin/gut inflammation research.

Adverse Effects

Limited direct human data.

Contraindications

No data.

Interaction Notes

Unknown.

Related Goals

Tissue Repair & RecoveryImmune SupportSkin & Hair

Available From

Amino Club

consumer RUO · COA: product page COA viewer

10 mg · $39.99 shown

Consumer RUO; review product details carefully

Product-level page and COA presentation make this a good fit for exact peptide routing from peptide, goal, and vendor pages.

USVisit Vendor

QC: third-party purity testing; product-level COA on page

Shipping: US/ROW (verify current policy) · affiliate: public program

Frequently Compared

BPC-157

Preclinical cytoprotective peptide studied for tissue repair and GI protection in animal models.

Tier C

Thymosin Beta-4

Actin-sequestering peptide with clinical data in ophthalmic wound healing and preclinical tissue repair.

Tier B-C

TB-500

Marketed thymosin beta-4 fragment (LKKTETQ actin-binding motif) studied for soft-tissue repair in preclinical models.

Tier C

Melanotan I

FDA-approved MC1R agonist (SCENESSE implant) for erythropoietic protoporphyria. Prescription only.

Tier A

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.